Boehringer Ingelheim, Lupin form tie-up

| Updated on September 04, 2019 Published on September 04, 2019

File photo   -  Bloomberg

Boehringer Ingelheim and Lupin have announced a licensing, development and commercialisation agreement for Lupin’s MEK inhibitor compound as a potential targeted therapy for patients with difficult-to-treat cancers.

The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harbouring a broad range of oncogenic KRAS mutations. The stock of Lupin gained 0.86 per cent at ₹741.50 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 04, 2019
This article is closed for comments.
Please Email the Editor